• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by STERIS plc (Ireland)

    5/20/25 4:10:47 PM ET
    $STE
    Industrial Specialties
    Health Care
    Get the next $STE alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001776271
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    STERIS plc
    SEC File Number
    001-38848
    Address of Issuer
    70 SIR JOHN ROGERSON'S QUAY
    DUBLIN
    IRELAND
    2
    Phone
    35312322000
    Name of Person for Whose Account the Securities are To Be Sold
    Majors Cary L
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Ordinary
    Charles Schwab & Co., Inc.
    3000 Schwab Way
    Westlake � TX � 76262
    128283208053.009825078905/20/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Ordinary05/20/2025Employee Stock Option ExerciseSTERIS plcCheckbox not checked1282805/20/2025Broker Payment for Cashless Exercise

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/20/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Cary L Majors

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $STE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STE

    DatePrice TargetRatingAnalyst
    10/24/2024$230.00 → $260.00Neutral → Overweight
    Piper Sandler
    2/6/2024$253.00Overweight
    KeyBanc Capital Markets
    5/30/2023$206.00Equal-Weight
    Morgan Stanley
    4/14/2023$215.00 → $197.00Overweight → Neutral
    Piper Sandler
    9/23/2022Buy → Hold
    Needham
    7/14/2022$240.00Overweight
    Piper Sandler
    4/7/2022$275.00Outperform
    Wolfe Research
    2/14/2022$250.00 → $270.00Market Outperform
    JMP Securities
    More analyst ratings

    $STE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/13/24 5:14:05 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/9/24 11:49:03 AM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/9/24 11:32:52 AM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Steris upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously

      10/24/24 6:28:31 AM ET
      $STE
      Industrial Specialties
      Health Care
    • KeyBanc Capital Markets resumed coverage on Steris with a new price target

      KeyBanc Capital Markets resumed coverage of Steris with a rating of Overweight and set a new price target of $253.00

      2/6/24 6:38:21 AM ET
      $STE
      Industrial Specialties
      Health Care
    • Morgan Stanley initiated coverage on Steris with a new price target

      Morgan Stanley initiated coverage of Steris with a rating of Equal-Weight and set a new price target of $206.00

      5/30/23 7:41:11 AM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and President, Healthcare Majors Cary L exercised 12,828 units of Ordinary Shares at a strike of $147.05 and sold $3,208,026 worth of Ordinary Shares (12,828 units at $250.08) (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      5/22/25 4:31:17 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SVP and President, Healthcare Majors Cary L sold $365,532 worth of Ordinary Shares (1,682 units at $217.32), decreasing direct ownership by 13% to 11,372 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      11/27/24 4:30:15 PM ET
      $STE
      Industrial Specialties
      Health Care
    • Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 91 units of Ordinary Shares, decreasing direct ownership by 0.27% to 33,251 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      10/2/24 4:37:12 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Financials

    Live finance-specific insights

    See more

    $STE
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $STE
    SEC Filings

    See more

    $STE
    Leadership Updates

    Live Leadership Updates

    See more
    • STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

      Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re

      5/14/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Declares Dividend of $0.57 per share

      DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se

      5/7/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025

      DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,

      4/22/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

      Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re

      5/14/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Declares Dividend of $0.57 per share

      DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se

      5/7/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025

      DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,

      4/22/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form 144 filed by STERIS plc (Ireland)

      144 - STERIS plc (0001757898) (Subject)

      5/20/25 4:10:47 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS plc (Ireland) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - STERIS plc (0001757898) (Filer)

      5/14/25 4:34:06 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by STERIS plc (Ireland)

      8-K - STERIS plc (0001757898) (Filer)

      3/3/25 5:03:38 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

      DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

      5/3/23 4:30:00 PM ET
      $CDMO
      $STE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • STERIS Announces Changes to Board of Directors

      David B. Lewis to retire at the Company's 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors. "We are grateful for David's long-term commitment to STERIS and will miss his unique perspective. W

      5/11/21 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care